Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Siu-Hin Wan, MD; Isabel Torres-Courchoud, MD, PhD; Paul M. McKie, MD; Joshua P. Slusser, BSc; Margaret M. Redfield, MD; John C. Burnett, Jr., MD; David O. Hodge, MS; Horng H. Chen, MBBCh

JACC: Basic to Translational Science (Dec 2019)

Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Siu-Hin Wan, MD,
Isabel Torres-Courchoud, MD, PhD,
Paul M. McKie, MD,
Joshua P. Slusser, BSc,
Margaret M. Redfield, MD,
John C. Burnett, Jr., MD,
David O. Hodge, MS,
Horng H. Chen, MBBCh

Affiliations

Siu-Hin Wan, MD: Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
Isabel Torres-Courchoud, MD, PhD: Hospital Reina Sofía, Tudela, Navarra, Spain
Paul M. McKie, MD: Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
Joshua P. Slusser, BSc: Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota
Margaret M. Redfield, MD: Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
John C. Burnett, Jr., MD: Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
David O. Hodge, MS: Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota
Horng H. Chen, MBBCh: Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota; Address for correspondence: Dr. Horng H. Chen, Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905.

Journal volume & issue: Vol. 4, no. 8
pp. 962 – 972

Abstract

Read online

Summary: Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow. (Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure; NCT01544998) Key Words: B-type natriuretic peptide, cardiorenal, heart failure, nesiritide, phosphodiesterase inhibition, systolic dysfunction

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal